USNA Share Price | USANA Health Sciences, Inc. Stock Analysis & Recommendation

Q: What does USANA Health Sciences, Inc. do?

Overview:USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products and operates in the Pharmaceuticals & Biotechnology industry within the micro-cap market.Financial Snapshot:Most recent Net Sales: 250 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 9 Million (Quarterly Results - Mar 2025) Market-cap: USD 567.07 Million (Micro Cap)Key Metrics:P/E: 16.00 Dividend Yield: 0.00% Debt Equity: -0.30 Return on Equity: 6.57% Price to Book: 1.07Contact Details:Address: 3838 W Parkway Blvd, SALT LAKE CITY UT: 84120-6336 Tel: 1 801 9547100 Website: https://www.usana.com/

Q: Is USANA Health Sciences, Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the Bollinger Bands, both showing bearish signals. The weekly MACD is mildly bullish, but this is overshadowed by the overall bearish indicators from the daily timeframe. Additionally, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -17.28% versus the S&P 500's 13.31%, and a one-year return of -23.08% compared to 16.64% for the index.

Q: Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 16, an EV to EBITDA of 4.61, and a Price to Book Value of 1.03. In comparison, Chromadex Corp. has a P/E of 39.82 and Nature's Sunshine Products, Inc. shows a P/E of 21.11, both indicating that USANA's valuation is not justified relative to its peers.The company's recent performance has been poor, with a year-to-date return of -42.74% compared to the S&P 500's 16.30%, and a staggering -73.15% return over the past five years against the S&P's 109.18%. This stark contrast reinforces the notion that USANA Health Sciences, Inc. is currently overvalued.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

108.36 k

Shareholding (Dec 2025)

FII

6.00%

Held by 80 FIIs

DII

65.42%

Held by 31 DIIs

Promoter

0.19%

How big is USANA Health Sciences, Inc.?

22-Jun-2025

As of Jun 18, USANA Health Sciences, Inc. has a market capitalization of 567.07 million and net sales of 876.24 million with a net profit of 34.81 million over the latest four quarters.

View full answer

What does USANA Health Sciences, Inc. do?

22-Jun-2025

USANA Health Sciences, Inc. develops and manufactures nutritional and personal care products, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $250 million and a market cap of $567.07 million.

View full answer

Who are in the management team of USANA Health Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of USANA Health Sciences, Inc. includes Chairman and CEO Kevin Guest, Lead Independent Director Gilbert Fuller, Senior Director Robert Anciaux, Director John Fleming, and Independent Directors Peggie Pelosi and Feng Peng. They oversee the company's strategic direction and operations.

View full answer

Is USANA Health Sciences, Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, USANA Health Sciences, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with year-to-date and one-year returns of -17.28% and -23.08%, respectively.

View full answer

Is USANA Health Sciences, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued with a P/E ratio of 16, poor recent performance (-42.74% year-to-date and -73.15% over five years), especially compared to its peers like Chromadex Corp. and Nature's Sunshine Products, Inc.

View full answer

Compare USANA Health Sciences, Inc. with Similar Stocks

Revolution Medicines, Inc.Nature's Sunshine Products, Inc.Chromadex Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared negative results for the last 7 consecutive quarters

INTEREST(HY) At USD 0.67 MM has Grown at 550.49%
OPERATING CASH FLOW(Y) Lowest at USD 63.01 MM
NET PROFIT(HY) At USD 19.06 MM has Grown at -29.34%

With ROE of 6.57%, it has a attractive valuation with a 1.03 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 321 Million (Micro Cap)

P/E

13.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.27

Return on Equity

4.67%

Price to Book

0.60

Revenue and Profits:

Net Sales:

226 Million

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-16.9%

6 Months

-45.17%

1 Year

-38.91%

2 Years

-65.42%

3 Years

-72.39%

4 Years

-78.86%

5 Years

-82.83%

USANA Health Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-4.00%

EBIT Growth (5y)

-22.03%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

1.70

Tax Ratio

47.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

65.57%

ROCE (avg)

70.81%

ROE (avg)

18.61%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.60

EV to EBIT

3.47

EV to EBITDA

1.95

EV to Capital Employed

0.45

EV to Sales

0.19

PEG Ratio

Dividend Yield

ROCE (Latest)

13.08%

ROE (Latest)

4.67%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 51 Schemes (28.35%)

Foreign Institutions

Held by 80 Foreign Institutions (6.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 5.85% vs -9.37% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 76.12% vs -164.42% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "226.20",
          "val2": "213.70",
          "chgp": "5.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "27.50",
          "val2": "10.80",
          "chgp": "154.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "-6.70",
          "chgp": "76.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "76.30%",
          "val2": "5.70%",
          "chgp": "7.06%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 8.29% vs -7.22% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -72.68% vs -34.01% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "925.30",
          "val2": "854.50",
          "chgp": "8.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.60",
          "val2": "88.60",
          "chgp": "2.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.30",
          "chgp": "166.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11.50",
          "val2": "42.10",
          "chgp": "-72.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "55.00%",
          "val2": "77.60%",
          "chgp": "-2.26%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

226.20

213.70

5.85%

Operating Profit (PBDIT) excl Other Income

27.50

10.80

154.63%

Interest

0.10

0.00

Exceptional Items

-13.40

0.00

Consolidate Net Profit

-1.60

-6.70

76.12%

Operating Profit Margin (Excl OI)

76.30%

5.70%

7.06%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 5.85% vs -9.37% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 76.12% vs -164.42% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

925.30

854.50

8.29%

Operating Profit (PBDIT) excl Other Income

90.60

88.60

2.26%

Interest

0.80

0.30

166.67%

Exceptional Items

-13.40

0.00

Consolidate Net Profit

11.50

42.10

-72.68%

Operating Profit Margin (Excl OI)

55.00%

77.60%

-2.26%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 8.29% vs -7.22% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -72.68% vs -34.01% in Dec 2024

All Annual Results

Company CV

About USANA Health Sciences, Inc.

USANA Health Sciences, Inc.

Pharmaceuticals & Biotechnology

USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.

Company Coordinates

Company Details

3838 W Parkway Blvd , SALT LAKE CITY UT : 84120-6336

Tel: 1 801 9547100

https://www.usana.com/

Registrar Details